United States and European Urea Cycle Disorder (UCD) Market Analysis & Outlook 2018-2019 & 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Urea
Cycle Disorder (UCD) Market in the US and Europe: Industry Analysis &
Outlook (2019-2023)” report has been added to ResearchAndMarkets.com’s
offering.

Urea cycle disorders (UCDs) are a group of orphan inherited defects of
six enzymes and two transporters that constitute the urea cycle in the
periportal liver cells. The age of onset symptoms vary between the
different types of UCDs. UCDs often occurs during the period of infancy
due to triggered postnatal catabolism. The diagnosis is made by analysis
of the urine and blood for abnormal metabolites (substance produced by
metabolism), and high ammonia levels. Frequent blood tests are done to
monitor ammonia levels. The treatment of urea cycle disorders consists
of dietary management to limit ammonia production. A liver transplant
can be an effective treatment for urea cycle disorder for the proper
functioning of urea cycle.

The urea cycle disorder treatment market in the U.S. and Europe is
expected to grow rapidly in the next few years. Several pharmaceutical
companies are under the development process of their late stage pipeline
drugs for urea cycle disorders. Factors such as, increasing healthcare
expenditures in the U.S, rise in the U.S. pharmaceutical R&D
expenditures and collaboration between pharmaceutical companies and
research institutes have driven the growth of the U.S. urea cycle
disorder treatment market. Further, upcoming launches of anti-UCD drugs
would contribute to the expansion of the urea cycle disorder treatment
market in the U.S. as well as in Europe.

The U.S. urea cycle disorder treatment market is dominated by certain
key players including Horizon Pharma Inc., Ultragenyx Pharmaceuticals
Inc., Aeglea Bio Therapeutics and Synlogix. Among all the key players,
Horizon Pharma ruled the U.S. UCD treatment market owing to the strong
performance of its product. Horizon’ Ravicti is the market leader due
its strong curative impact on the patients with UCD. The remaining key
players have their products under the development process of pipeline
drugs for UCDs. There would be a generic competition between the
upcoming anti-UCD drugs in the coming years.

Key Topics Covered:

1. Overview

1.1 Urea Cycle

1.2 Process of Urea Cycle

1.3 Urea Cycle Disorder (UCD)

1.4 Types of UCDs and Their Management

1.5 Diagnosis and Treatment of UCD

2. The U.S. Market Analysis

2.1 The U.S. Total UCD Population Forecast

2.2 The U.S. Existing and New UCD Population Forecast

2.3 The U.S. Diagnosed UCD Population Forecast

2.4 The U.S. UCD Drug Market

2.4.1 The U.S. Ravicti Revenue

2.4.2 The U.S. Ravicti Revenue Forecast

2.4.3 The U.S KB195 Revenue Forecast

2.4.4 The U.S. UCD Population Treated with KB195 Forecast

3. Europe Market Analysis

3.1 Europe UCD Population Forecast

3.2 Europe Existing and New UCD Population Forecast

3.3 Europe Diagnosed UCD Population Forecast

3.4 Europe UCD Drug Market

3.4.1 Europe KB195 Revenue Forecast

3.4.2 Europe UCD Population Treated with KB195 Forecast

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Increasing Healthcare Expenditure in the U.S.

4.1.2 Rise in Pharmaceutical R&D Expenditures in the U.S.

4.1.3 Collaboration of Pharmaceutical Companies with Research Institutes

4.2 Key Trends and Development

4.2.1 Shifts in the Newborn Population in the U.S. and Europe

4.2.2 Upcoming Launches of Anti-UCD Drugs

4.2.3 Development of Orphan Drugs for Urea Cycle Disorder

4.3 Challenges

4.3.1 Less Definitive Treatment Options

4.3.2 High Healthcare and Medical Costs

4.3.3 Stringent Medical Regulations

5. Competitive Landscape

5.1 Key Players – Drugs Pipeline in the Urea Cycle Disorder Space

5.2 Key Players – Revenue Comparison

5.3 Key Players – Market Capital Comparison

6. Company Profiles

6.1 Horizon Pharma Plc.

6.1.1 Business Overview

6.1.2 Financial Overview

6.1.3 Business Strategies

6.2 Ultragenyx Pharmaceuticals Inc.

6.3 Aeglea Bio Therapeutics

6.4 Synlogix

For more information about this report visit https://www.researchandmarkets.com/r/6x4ml8

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Urology
and Nephrology